- ►annals.org [PDF] D Kirpichnikov, SI McFarlane, JR Sowers - Annals of internal medicine, 2002 - Am Coll Physicians Metformin is an insulin-sensitizing agent with potent antihyper- glycemic
properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus
is similar to that of sulfonylureas, thia- zolidinediones, and insulin. ... Cited by 350 - Related articles - BL Direct - All 6 versions
CJ Bailey, RC Turner - New England Journal of Medicine, 1996 - content.nejm.org Metformin (dimethylbiguanide) is an orally administered drug used to lower blood
glucose concentrations in patients with non-insulin-dependent diabetes mellitus
(NIDDM). 1 It improves insulin sensitivity and thus decreases the insulin ... Cited by 714 - Related articles - BL Direct - All 5 versions
- ►karolinskauniversitetssjukhuset.se [PDF] SR Salpeter, E Greyber, GA Pasternak, EE … - Archives of Internal Medicine, 2003 - archinte.highwire.org Methods A comprehensive search was performed to identify all comparative trials
or observational cohort studies published between January 1, 1959, and March 31,
2002, that evaluated metformin therapy, alone or in combination with other ... Cited by 320 - Related articles - BL Direct - All 16 versions
MG Wulffele, A Kooy, D Zeeuw, CDA … - Journal of Internal Medicine, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 81 - Related articles - BL Direct - All 6 versions
RA DeFronzo, AM Goodman… - New England Journal of Medicine, 1995 - content.nejm.org Results In protocol 1, at the end of the study the 143 patients in the metformin
group, as compared with the 146 patients in the placebo group, had lower mean
(±SE) fasting plasma glucose concentrations (189±5 vs. 244±6 mg per ... Cited by 440 - Related articles - All 7 versions
DK Nagi, JS Yudkin - Diabetes Care, 1993 - Am Diabetes Assoc OBJECTIVE--To investigate the effects of metformin on glycemic control, insulin
resistance, and risk factors for cardiovascular disease in NIDDM subjects from
two ethnic groups (Caucasian and Asian) with different risks of ... Cited by 247 - Related articles - BL Direct - All 5 versions
MD Garber, J Alan, MD Duncan, G Theodore, … - The American journal of medicine, 1997 - Elsevier RESULTS: Metformin improved glucose variables as compared with placebo. The
adjusted mean changes in fasting plasma glucose from baseline associated with
each metformin group at week 7, 11, or at endpoint exceeded those ... Cited by 234 - Related articles - BL Direct - All 4 versions
- ►nih.gov G Zhou, R Myers, Y Li, Y Chen, X Shen, J … - Journal of Clinical Investigation, 2001 - Am Soc Clin Investig Metformin is a widely used drug for treatment of type 2 diabetes with no defined
cellular mechanism of action. Its glucose-lowering effect results from decreased
hepatic glucose production and increased glucose utilization. Metformin's ... Cited by 1108 - Related articles - BL Direct - All 7 versions
RI Misbin, L Green, BV Stadel, JL Gueriguian … - The New England Journal of Medicine, 1998 - nejm.highwire.org On the basis of the reports received by the FDA, congestive heart failure has
recently been included as a contraindication to metformin therapy. The revised
label also states that metformin therapy should be withheld in patients ... Cited by 223 - Related articles - All 5 versions
- ►annals.org [PDF] RA DeFronzo - Annals of internal medicine, 1999 - Am Coll Physicians Type 2 diabetes mellitus is a chronic metabolic disorder that results from
defects in both insulin secretion and insulin action. An elevated rate of basal
hepatic glucose production in the presence of hyperinsulinemia is the pri- ... Cited by 784 - Related articles - BL Direct - All 14 versions
